Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
A 2-part, multicenter, Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of upamostat in adult patients with COVID-19 disease who do not require inpatient care.
Epistemonikos ID: cfe3d3d5ac4ccb8dc6c4a5b140842ae5ad87f1f4
First added on: Jan 26, 2021